Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial

医学 前列腺切除术 雄激素剥夺疗法 前列腺癌 临床终点 放射治疗 泌尿科 曲普瑞林 人口 内科学 外科 肿瘤科 随机对照试验 癌症 激素 促黄体激素 促性腺激素释放激素 环境卫生
作者
Paul Sargos,Sylvie Chabaud,I. Latorzeff,Nicolas Magné,Ahmed Benyoucef,S. Supiot,Dominique Pasquier,Menouar Samir Abdiche,O. Gilliot,P. Graff-Cailleaud,Marlon Silva,Philippe Bergerot,Pierre Baumann,Yazid Belkacémi,D. Azria,Meryem Brihoum,M. Soulié,Pierre Richaud
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (10): 1341-1352 被引量:232
标识
DOI:10.1016/s1470-2045(20)30454-x
摘要

Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance.GETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069.Between March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50-100), 74 months (47-100) in the adjuvant radiotherapy group and 78 months (52-101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86-95) in the adjuvant radiotherapy group and 90% (85-94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48-1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001).Although our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events.French Health Ministry and Ipsen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可爱的函函应助香蕉静芙采纳,获得10
刚刚
张浩发布了新的文献求助10
刚刚
1秒前
fei发布了新的文献求助150
1秒前
2秒前
2秒前
3秒前
依灵完成签到,获得积分10
3秒前
3秒前
充电宝应助mariawang采纳,获得10
4秒前
王哈哈关注了科研通微信公众号
5秒前
kkdkg发布了新的文献求助10
5秒前
时笙发布了新的文献求助10
5秒前
苏利文完成签到,获得积分10
6秒前
6秒前
小二郎应助尔尔采纳,获得30
6秒前
7秒前
小丑鱼儿发布了新的文献求助10
7秒前
8秒前
Rubby应助Sissi采纳,获得10
8秒前
9秒前
隐形夕阳发布了新的文献求助50
10秒前
搞学术的发布了新的文献求助10
10秒前
Freddie发布了新的文献求助10
12秒前
淡淡梦容发布了新的文献求助10
12秒前
12秒前
mmol发布了新的文献求助10
13秒前
可靠的冰烟完成签到,获得积分10
13秒前
Ava应助kkdkg采纳,获得10
14秒前
Bio应助AA简单男孩采纳,获得26
15秒前
搜集达人应助虚幻靖易采纳,获得10
15秒前
Notdodead应助yyds采纳,获得10
15秒前
科研通AI2S应助Lu采纳,获得10
15秒前
16秒前
16秒前
搞怪的人龙完成签到,获得积分10
17秒前
淡淡梦容完成签到,获得积分10
17秒前
情怀应助star采纳,获得10
18秒前
19秒前
19秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021